Are lamotrigine, brivaracetam, and sodium valproate used to treat emotional dysregulation in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lamotrigine, Brivaracetam, and Sodium Valproate for Emotional Dysregulation in Children

These medications are NOT indicated for treating emotional dysregulation in children as a primary diagnosis. However, sodium valproate and lamotrigine have established roles in treating bipolar disorder in children (which includes mood instability), while brivaracetam has no role in treating emotional or behavioral symptoms.

Medication-Specific Evidence

Sodium Valproate (Valproate)

Valproate has the strongest evidence for treating acute mania in children with bipolar disorder 1. In pediatric bipolar disorder studies, valproate monotherapy achieved a 53% response rate for manic symptoms 2. When combined with quetiapine, response rates increased to 87% 2.

  • FDA-approved for acute mania in adults; commonly used off-label in children 1
  • Recommended as first-line treatment for pediatric bipolar disorder with or without psychotic features 1
  • Critical safety concern: MHRA safety measures must be followed, particularly regarding use in females of childbearing potential due to teratogenicity and neurodevelopmental risks 3
  • Dosing: Start 15 mg/kg/day, increase by 5-10 mg/kg/week, maximum 60 mg/kg/day 4

Lamotrigine

Lamotrigine is primarily effective for bipolar depression and maintenance therapy, NOT for acute mania or general emotional dysregulation 1.

  • FDA-approved for maintenance therapy in adults with bipolar disorder 1
  • Evidence suggests efficacy in adolescents (13-17 years) but NOT in younger children (10-12 years) for bipolar disorder 5
  • Open-label data support use in adolescent bipolar depression 1
  • Major limitation: Does not treat acute manic symptoms or general aggression 6
  • Safety concern: Risk of Stevens-Johnson syndrome requires slow titration; avoid in patients with HLA-B*15:02 positive genotype 3

Brivaracetam

Brivaracetam has NO role in treating emotional dysregulation or any psychiatric symptoms in children. This medication is an antiepileptic drug indicated solely for epilepsy 7.

  • FDA-approved only for partial-onset seizures
  • Psychiatric adverse effects: Causes irritability, anxiety, aggression, mood swings, and psychotic symptoms in 13% of patients 7
  • Would worsen, not improve, emotional dysregulation
  • Listed as add-on medication option for epilepsy, not psychiatric conditions 3

Clinical Decision Algorithm

If the child has diagnosed bipolar disorder:

  1. For acute mania: Use valproate or atypical antipsychotics (aripiprazole, risperidone, quetiapine, olanzapine) 1, 8
  2. For bipolar depression: Consider lamotrigine in adolescents ≥13 years 5
  3. For maintenance: Lithium (age ≥12), lamotrigine, or valproate 1

If the child has emotional dysregulation WITHOUT bipolar disorder:

  • These medications are NOT appropriate first-line treatments 1
  • Evaluate for ADHD, anxiety, trauma, developmental disorders, or environmental factors 1
  • Address psychosocial interventions first 1, 9
  • If medication needed for severe aggression: Consider atypical antipsychotics (risperidone) or stimulants if ADHD present 10

Critical Caveats

Diagnostic validity concerns: The diagnosis of bipolar disorder in young children (<12 years) remains controversial and poorly validated 1. Highly volatile and reactive children require comprehensive assessment for developmental disorders, psychosocial stressors, and temperamental factors before applying a bipolar diagnosis 1.

Valproate restrictions: Given teratogenicity risks and potential neurodevelopmental effects in offspring (even from paternal exposure), valproate use requires strict adherence to pregnancy prevention programs in females of childbearing potential 11.

Polypharmacy considerations: Combination therapy (mood stabilizer + atypical antipsychotic) is often necessary but should be implemented systematically with clear rationale 1, 9. Avoid unnecessary polypharmacy targeting behavioral symptoms without clear psychiatric diagnosis 10, 9.

References

Guideline

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

Research

Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.

Acta psychiatrica Scandinavica. Supplementum, 2005

Guideline

practice parameter on the use of psychotropic medication in children and adolescents.

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.